Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Debt to Equity (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Debt to Equity for 11 consecutive years, with $0.36 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 95.11% year-over-year to $0.36, compared with a TTM value of $0.36 through Dec 2025, down 95.11%, and an annual FY2025 reading of $0.51, down 75.4% over the prior year.
  • Debt to Equity was $0.36 for Q4 2025 at Arrowhead Pharmaceuticals, down from $0.51 in the prior quarter.
  • Across five years, Debt to Equity topped out at $7.3 in Q4 2024 and bottomed at $0.36 in Q4 2025.